The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
MishinaT., OdaK., MurataS.Mitomycin C bladder instillation therapy for bladder tumors.J Urol.1975; 114(2): 217–9.
2.
SomervilleJ.J., NewlingD.W., RichardsB.Mitomycin C in superficial bladder cancer: 24-month follow-up.Br J Urol.1985; 57(6): 686–9.
3.
HarrisonG.S., GreenD.F., NewlingD.W.A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.Br J Urol.1983; 55(6): 676–9.
4.
DeFuriaM.D., BrackenR.B., JohnsonD.E.Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: An interim report.Cancer Treat Rep.1980; 64(2-3): 225–30.
5.
BrackenR.B., SwansonD.A., JohnsonD.E.Role of intravesical mitomycin C in management of superficial bladder tumors.Urology.1980; 16(1): 11–5.
6.
GofritO.N., ShapiroA., PodeD.Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.Urology.2004; 63(3): 466–71.
SolowayM.S.Treatment of superficial bladder cancer with intravesical mitomycin C: Analysis of immediate and long-term response in 70 patients.J Urol.1985; 134(6): 1107–9.
9.
VegtP.D., WitjesJ.A., WitjesW.P.A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.J Urol.1995; 153(3 pt 2): 929–33.
10.
ColomboR., BrausiM., Da PozzoL.Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication: A pilot study on marker lesion.Eur Urol.2001; 39(1): 95–100.
11.
MalmströmP.U., WijkströmH., LundholmC.Five-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.J Urol.1999; 161(4): 1124–7.
12.
Di StasiS.M., GiannantoniA., StephenR.L.Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study.J Urol.2003; 170(3): 777–82.
13.
ProutG.R., GriffinP.P., NocksB.N.Intravesical therapy of low stage bladder carcinoma with mitomycin C: Comparison of results in untreated and previously treated patients.J Urol.1982; 127(6): 1096–8.
14.
KoontzW.W.Jr, HeneyN.M., SolowayM.S.Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.Urology.1985; 26(4 suppl): 30–1.
15.
HeneyN.M., KoontzW.W., BartonB.Intravesical thiotepa versus mitomycin C in patients with Ta, T1, and TIS transitional cell carcinoma of the bladder: A phase III prospective randomized study.J Urol.1988; 140(6): 1390–3.
16.
De BruijnE.A., SleeboomH.P., van HelsdingenP.J.Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times.Int J Cancer.1992; 51(3): 359–64.
17.
ColomboR., Da PozzoL.F., LevA.Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.J Urol.1998; 159(3): 783–7.
18.
MalmströmP.U.A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder.BJU Int.2002; 89(7): 681–6.
19.
HamdyF.C., HastieK.J., KerryR.Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment?Br J Urol.1993; 71(2): 183–6.
20.
RintalaE., JauhiainenK., AlfthanO.Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.Prog Clin Biol Res.1989; 310: 271–4.
21.
RintalaE., JauhiainenK., AlfthanO.Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer.Eur Urol.1991; 20(1): 19–25.
22.
JauhiainenK., SotarautaM., PermiJ.Effect of mitomycin C and doxorubicin instillation on carcinoma in situ of the urinary bladder. A Finnish multicenter study.Eur Urol.1986; 12(1): 32–7.
23.
JauhiainenK., AlfthanO.Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer.Br J Urol.1987; 60(1): 54–9.
24.
NiijimaT., KoisoK., AkazaH.Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.Cancer Chemother Pharmacol.1983; 11(suppl): S79–82.
25.
IsakaS., OkanoT., ShimazakiJ.Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C.Cancer Chemother Pharmacol.1987; 20(suppl): S77–80.
26.
AkazaH., KoisoK., KotakeT.Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin.Cancer Chemother Pharmacol.1992; 30(suppl): S15–20.
27.
AuJ.L., BadalamentR.A., WientjesM.G.International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial.J Natl Cancer Inst.2001; 93(8): 597–604.
28.
LockhartJ.L., ChaikinL., BondhusM.J.Prostatic recurrences in the management of superficial bladder tumors.J Urol.1983; 130(2): 256–7.
29.
HulandH., KloppelG., FeddersenI.Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: Final evaluation of a prospective multicenter study with 419 patients.J Urol.1990; 144(1): 68–71.
30.
ParoniR., SaloniaA., LevA.Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.Br J Clin Pharmacol.2001; 52(3): 273–8.
31.
HulandH., OttoU.Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients.Eur Urol.1983; 9(2): 84–6.
32.
HulandH., OttoU., DroeseM.Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: Influence on recurrence, progression, and survival.J Urol.1984; 132(1): 27–9.
33.
DeBruyneF.M., van der MeijdenA.P., GeboersA.D.BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.Urology.1988; 31(3 suppl): 20–5.
34.
DebruyneF.M., van der MeijdenA.P., FranssenM.P.BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.Prog Clin Biol Res.1989; 303: 435–46.
35.
da SilvaF.C., FerritoF., BrandaoT., SantosA.4′-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.Eur Urol.1992; 21(1): 42–4.
36.
BouffiouxC., KurthK.H., BonoA.Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.J Urol.1995; 153(3 pt 2): 934–41.
37.
WitjesW.P., WitjesJ.A., OosterhofG.O.Update on the Dutch Cooperative Trial: Mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.Semin Urol Oncol.1996; 14(1 suppl 1): 10–6.
38.
WitjesJ.A., MeijdenA.P., SylvesterL.C.Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.Urology.1998; 52(3): 403–10.
39.
TsushimaT., MatsumuraY., OzakiY.Prophylactic intravesical instillation therapy with adriamycin and mitomycin C in patients with superficial bladder cancer.Cancer Chemother Pharmacol.1987; 20(suppl): S72–6.
40.
HiraoY., OkajimaE., OharaS.Prophylactic treatment for superficial bladder cancer following transurethral resection.Cancer Chemother Pharmacol.1987; 20(suppl): S85–90.
41.
KondasJ., KissL., HatarA.The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.Int Urol Nephrol.1999; 31(4): 451–6.
42.
FlaniganR.C., EllisonM.F., ButlerK.M.A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.J Urol.1986; 136(1): 35–7.
43.
BoccardoF., CannataD., RubagottiA.Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: Results of a multicentric Italian study.J Clin Oncol.1994; 12(1): 7–13.
44.
MinerviniR., FelipettoR., ViganoL.Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.Urol Int.1996; 56(4): 234–7.
45.
HurleR., ManzettiA., LosaA.Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: Long-term results.Urol Int.1998; 61(4): 220–6.
46.
BrausiM., CampoB., PizzocaroG.Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative Phase II study.Urology.1998; 51(3): 506–9.
47.
WitjesJ.A., CarisC.T., MunganN.A.Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.J Urol.1998; 160(5): 1668–71.
48.
ZinckeH., BensonR.C.Jr, HiltonJ.F.Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: A prospective, randomized, stratified study with crossover design.J Urol.1985; 134(6): 1110–4.
49.
TolleyD.A., HargreaveT.B., SmithP.H.Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: Interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).Br Med J (Clin Res Ed).1988; 296(6639): 1759–61.
50.
TolleyD.A., ParmarM.K., GrigorK.M.The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up.J Urol.1996; 155(4): 1233–8.
51.
RigattiP., LevA., ColomboR.Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study.Eur Urol.1991; 20(3): 204–10.
52.
ColomboR., LevA., Da PozzoL.F.A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment.J Urol.1995; 153(3 pt 2): 959–63.
